Broad spectrum post-entry inhibitors of coronavirus replication: Cardiotonic steroids and monensin
Shahrzad Jahanshahi, Hong Ouyang, C. M. Sabbir Ahmed, Ali Zahedi‐Amiri, Subha Dahal, Yu-Qian Mao, David A. J. Van Ommen, Ramy Malty, Wenming Duan, Terek Been, Javier Hernandez, Maria Mangos, Jocelyn Nurtanto, Mohan Babu, Liliana Attisano, Walid A. Houry, Theo J. Moraes, Alan Cochrane
Abstract
A small molecule screen identified several cardiotonic steroids (digitoxin and ouabain) and the ionophore monensin as potent inhibitors of HCoV-229E, HCoV-OC43, and SARS-CoV-2 replication with EC50s in the low nM range. Subsequent tests confirmed antiviral activity in primary cell models including human nasal epithelial cells and lung organoids. Addition of digitoxin, ouabain, or monensin strongly reduced viral gene expression as measured by both viral protein and RNA accumulation. Furthermore, the compounds acted post virus entry. While the antiviral activity of digitoxin was dependent upon activation of the MEK and JNK signaling pathways but not signaling through GPCRs, the antiviral effect of monensin was reversed upon inhibition of several signaling pathways. Together, the data demonstrates the potent anti-coronavirus properties of two classes of FDA approved drugs that function by altering the properties of the infected cell, rendering it unable to support virus replication.